Cancer Center Support Grant

癌症中心支持补助金

基本信息

批准号：
10178288
负责人：
MICHELLE M LE BEAU
金额：
$ 10.42万
依托单位：
UNIVERSITY OF CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
起止时间：
1997-09-01 至 2023-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10178288
关键词：
Address Antibodies Area Award Basic Science Bioinformatics Biological Biological Markers Biometry Cancer Burden Cancer Center Support Grant Cancer Control Cancer Control Research Cancer Diagnostics Cancer Etiology Cancer Model Cancer Patient Cancer Research Project Catchment Area Chicago Classification Clinical Clinical Data Clinical Investigator Clinical Protocols Clinical Research Clinical Sciences Clinical Treatment Clinical Trials Cohort Studies Collaborations Communities Community Outreach Comprehensive Cancer Center Conduct Clinical Trials County Cyclic GMP Cytometry Development Diagnostic Procedure Education Environment Environmental Risk Factor Evaluation Faculty Funding Future Genetic Genomics Goals Head and Neck Cancer Health Health Professional Hematologic Neoplasms Hospitals Human Illinois Image Imaging Techniques Immune Immunologic Monitoring Incidence Indiana Intervention Investigation Investigational Drugs Investigational Therapies Laboratories Lead Leadership Malignant Neoplasms Medical Medicine Methods Microscopy Minority Groups Mission Modality Modeling Molecular Monitor Oncology Outcome Patient Care Pediatric Oncology Group Peer Review Pharmacogenomics Pharmacology Phase Physicians Population Population Sciences Population Sizes Prevention Preventive Process Protocols documentation Publications Quality of life Research Research Personnel Research Project Grants Resistance Resource Sharing Resources Risk Scientist Site Smoking Strategic Planning Students System Technology Testing Therapeutic Therapeutic procedure Training Training and Education Transgenic Mice Translational Research Underrepresented Minority Underrepresented Populations Universities Woman animal imaging anticancer research base cancer care cancer education cancer genetics cancer health disparity cancer prevention cancer risk career clinical care colorectal cancer screening cooking data management data registry diagnostic biomarker drug development early phase clinical trial effective intervention effective therapy embryonic stem cell ethnic minority population experience genetic approach high risk behavior high risk population human tissue improved individual patient innovation investigator-initiated trial male member metropolitan mortality mortality disparity multidisciplinary next generation novel novel diagnostics novel strategies novel therapeutics outreach outreach program patient population pre-clinical prevent profession allied to medicine programs survivorship tissue resource treatment program treatment response tumor tumor immunology tumor registry underserved minority

项目摘要

ABSTRACT The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) is submitting this competitive renewal application for its Cancer Center Support Grant for Years 43-47. The mission of the UCCCC is to elucidate the determinants of cancer, to develop cures for cancer, and to prevent cancer through research, clinical care, education, and community engagement. Our cancer research programs emphasize translational and transdisciplinary research, and we pursue this goal by promoting collaboration among a diverse and dedicated team of outstanding basic, translational, clinical, and population researchers. The 166 members of the UCCCC are organized into five established programs, all with a translational focus (Molecular Mechanisms of Cancer; Immunology and Cancer; Clinical and Experimental Therapeutics; Advanced Imaging; and Cancer Prevention and Control). Clinical research is a major focus of multidisciplinary activity at the UCCCC. The UCCCC has an extensive record in conducting all phases of clinical trials, and was awarded a U10 NCTN Lead Academic Participating Site (LAPS) award from the NCI. In addition, the UCCCC is a full member of the Alliance for Clinical Trials in Oncology, and the Children's Oncology Group (COG), and participates in NRG Oncology studies as a LAPS main member. In 2016, 914 individual patients were accrued to therapeutic protocols, with 383 accrued to investigator-initiated trials. In the period since the last review (2013-2016), the UCCCC contributed 2,121 peer-reviewed publications. Members are supported by $40.5 million (DC) in peer- reviewed funding, and $23.7 million in non-peer-reviewed funding. Funds are requested in this application for Program Leaders; Leadership, Planning and Evaluation; Developmental Funds, Administration, Clinical Protocol and Data Management; the Protocol Review and Monitoring System, Community Outreach and Engagement; Cancer Research Career Enhancement and Related Activities; and 10 shared resources (Bioinformatics, Biostatistics; Cytometry and Antibody Technology; Genomics; Human Immunologic Monitoring and cGMP; Human Tissue Resource Center; Integrated Microscopy; Integrated Small Animal Imaging Research Resource; Pharmacology; and Transgenic Mouse/Embryonic Stem Cell Facilities). Through an in-depth institutional review and multi-faceted strategic planning process, the UCCCC has new and strong institutional commitments, and a stable and experienced leadership team, and has developed and implemented a comprehensive strategic plan. Future development will focus on three major initiatives, which prioritize and accelerate laboratory, clinical and translational, and community-based cancer research: 1) developing new biomarkers, novel treatments, and new interventions to prevent cancer; 2) efficiently integrating effective treatments and interventions into medical practice; and 3) assessing the impact of these new approaches on health outcomes, and addressing cancers relevant to our catchment area. Underpinning each of these initiatives is computation-based models for cancer research and care.

抽象的芝加哥大学医学综合癌症中心 (UCCCC) 正在提交这份竞争性的癌症中心 43-47 年支持补助金的续签申请。 UCCCC 的使命是阐明癌症的决定因素，开发癌症的治疗方法，并通过研究预防癌症，临床护理、教育和社区参与。我们的癌症研究项目强调转化和跨学科研究，我们通过促进多元化和跨学科研究之间的合作来实现这一目标由杰出的基础、转化、临床和人口研究人员组成的专业团队。 166名成员 UCCCC 分为五个既定项目，所有项目均以转化为重点（分子机制癌症；免疫学和癌症；临床和实验治疗学；高级成像；和癌症预防和控制）。临床研究是 UCCCC 多学科活动的主要焦点。这 UCCCC 在开展各阶段临床试验方面拥有丰富的记录，并被授予 U10 NCTN NCI 颁发的首席学术参与站点 (LAPS) 奖。此外，UCCCC 是该组织的正式成员。肿瘤学临床试验联盟和儿童肿瘤学组 (COG)，并参加 NRG 肿瘤学研究作为 LAPS 主要成员。 2016 年，共有 914 名患者接受了治疗协议，其中 383 项是由研究者发起的试验产生的。自上次审查以来（2013 年至 2016 年）， UCCCC 贡献了 2,121 篇同行评审出版物。会员获得 4050 万美元（DC）的同行支持审查资金，以及 2370 万美元的非同行审查资金。本申请中要求为项目负责人提供资金；领导、规划和评估；发展基金、管理、临床方案和数据管理；方案审查和监控系统、社区外展和参与；癌症研究职业提升和相关活动；和 10 个共享资源（生物信息学、生物统计学；细胞计数和抗体技术;基因组学；人体免疫监测和 cGMP；人体组织资源中心；集成显微镜；综合小动物成像研究资源；药理;和转基因小鼠/胚胎干细胞设施）。通过深入的机构审查和多方面的战略规划过程，UCCCC 有了新的和强有力的制度承诺，以及稳定且经验丰富的领导团队，并已发展和实施了全面的战略计划。未来发展将重点推进三大举措：优先考虑并加速实验室、临床和转化以及基于社区的癌症研究： 1）开发新的生物标志物、新的治疗方法和新的干预措施来预防癌症； 2）高效将有效的治疗和干预措施融入医疗实践； 3）评估这些影响健康结果的新方法，以及解决与我们流域相关的癌症的问题。支撑这些举措中的每一项都是基于计算的癌症研究和护理模型。